Hematologic Responses to Molidustat in Cats with Anemia of Heterogeneous Etiology: A Retrospective Descriptive Study.
- 1Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
- 2Korea Animal Medical Center, Cheongju 28651, Republic of Korea.
Abstract
Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for nonregenerative anemia associated with chronic kidney disease (CKD) in cats but is also used for anemia of other causes. This retrospective, single-center study described the hematologic response to molidustat in 39 cats with anemia of heterogeneous etiology and identified factors that complicate attribution of improvement to the drug. Response was defined as a hematocrit (HCT) increase of ≥4 percentage points from baseline at the complete blood count closest to day 28 (days 14-45), without transfusion to treat anemia. Molidustat was used outside the approved indication in 33 cats (84.6%). Seventeen cats (43.6%) had a response-window measurement; they had a longer treatment span and differed in etiology and concurrent treatment from non-evaluable cats. Among these 17 cats, 12 (70.6%; 95% CI 46.9-86.7%) met the response criterion; sensitivity analyses specified before formal analysis gave 70.6-75.0% and post hoc attribution analyses 29.4-50.0%. In 7 of the 12 responders, darbepoetin or transfusion preceded the qualifying measurement, or it was obtained more than 7 days after the last dose. These data describe clinical use but do not establish effectiveness outside CKD-associated anemia.
Related
- Pain experiences of Tibetan children with hematologic malignancies in China: A descriptive phenomenological study
- Clinical Comparator Dependence of Inflammatory and Hematologic Biomarker Discrimination for Sepsis: A Matched Retrospective Study Using MIMIC-IV Emergency Department Data
- Medical Encounters During the 2026 AETF European Taekwon-Do Championships: A Five-Day Retrospective Descriptive Study
- Study on the clinical outcomes of COVID-19 infection and immune responses following the third booster dose of inactivated COVID-19 vaccine in hematologic disease patients
- Sepsis and Chronic Liver Disease: Mortality and Prognostic Factors. A 12-Year Retrospective Analytical-Descriptive Observational Study Sepsis y hepatopatía crónica: mortalidad y factores pronósticos. Estudio observacional analítico-descriptivo retrospectivo de 12 años
BibTeX
@article{lee2026hematologic,
title = {{Hematologic Responses to Molidustat in Cats with Anemia of Heterogeneous Etiology: A Retrospective Descriptive Study.}},
author = {Gippeum Lee and Jeongmin Lee and Kun-Ho Song},
journal = {Veterinary sciences},
year = {2026},
month = oct,
doi = {10.3390/vetsci13101075},
url = {https://europepmc.org/article/MED/42944170},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hematologic Responses to Molidustat in Cats with Anemia of Heterogeneous Etiology: A Retrospective Descriptive Study.
AU - Gippeum Lee
AU - Jeongmin Lee
AU - Kun-Ho Song
PY - 2026
DA - 2026/10/11
JO - Veterinary sciences
DO - 10.3390/vetsci13101075
UR - https://europepmc.org/article/MED/42944170
AB - Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for nonregenerative anemia associated with chronic kidney disease (CKD) in cats but is also used for anemia of other causes. This retrospective, single-center study described the hematologic response to molidustat in 39 cats with anemia of heterogeneous etiology and identified factors that complicate attribution of improvement to the drug. Response was defined as a hematocrit (HCT) increase of ≥4 percentage points from baseline at the complete blood count closest to day 28 (days 14-45), without transfusion to treat anemia. Molidustat was used outside the approved indication in 33 cats (84.6%). Seventeen cats (43.6%) had a response-window measurement; they had a longer treatment span and differed in etiology and concurrent treatment from non-evaluable cats. Among these 17 cats, 12 (70.6%; 95% CI 46.9-86.7%) met the response criterion; sensitivity analyses specified before formal analysis gave 70.6-75.0% and post hoc attribution analyses 29.4-50.0%. In 7 of the 12 responders, darbepoetin or transfusion preceded the qualifying measurement, or it was obtained more than 7 days after the last dose. These data describe clinical use but do not establish effectiveness outside CKD-associated anemia.
SN - 2306-7381
ER -